Overview:
A9 Biopharma designs cleavable and non-cleavable linkers for antibody–drug conjugates (ADCs) and PROTAC molecules, enabling precise control over stability, targeting, and payload delivery.

Capabilities:

• Val-Cit, PEG-based, and custom linker architectures
• Compatibility with diverse antibodies, payloads, E3 ligase ligands, and target binders
• Scalable synthesis with complete analytical characterization

Benefits:

• Enable advanced biotherapeutic design
• Reliable, scalable linkers for research and clinical pipelines
• Optimized performance for ADC and PROTAC development